Ultragenyx drug fails pivotal Phase 3, FDA’s success at regulating unproven stem cells, and other biotech news Photo illustration: Christine Kao/STAT; Photo: Adobe Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, a crushing Phase 3 failure for Ultragenyx in Angelman syndrome, a new accelerator from Nobel laureate David Baker to use AI to map nature’s design rules, and more. The sniffly 5-year-old in my bed is coloring a remarkable green-blue rainbow at present. Visionary, truly. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Meghana Keshavan covers biotech and contributes to The Readout newsletter.
STAT+: Seattle scientists launch $95 million AI biology effort
Full Article
Original Source
Read the full article at Statnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.